Skip to main content

Table 6 Association between POAF and post-operative outcomes in 156 subjects

From: A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis

Post-operative outcomes

Total*, n (%)

Non-POAF group, n (%)

POAF group, n (%)

p value

Stroke

 Yes

4 (4.0)

2 (50)

2 (50)

0.58

 No

97 (96.0)

69 (71.1)

28 (28.9)

 

Sternal infection

 Yes

3 (3.0)

3 (100)

0 (0)

0.55

 No

98 (97.0)

68 (69.4)

30 (30.6)

 

Respiratory problems

 Yes

6 (5.9)

3 (50)

3 (50)

0.36

 No

95 (94.1)

68 (71.6)

27 (28.4)

 

Renal failure requiring dialysis

 Yes

5 (5.0)

4 (80)

1 (20)

1.00

 No

96 (95.0)

67 (69.8)

29 (30.2)

 

Endocrine problems

 Yes

1 (1.0)

1 (100.0)

0 (0)

1.00

 No

100 (99.0)

70 (70.0)

30 (30.0)

 

Pleural effusion

 Yes

5 (5.0)

3 (60)

2 (40)

0.63

 No

96 (95.0)

68 (70.8)

28 (29.2)

 

Cardiac tamponade

 Yes

14 (13.9)

13 (92.9)

1 (7.1)

0.06

 No

87 (86.1)

58 (66.7)

29 (33.3)

 

Fever

 Yes

6 (5.9)

4 (66.7)

2 (33.3)

1.00

 No

95 (94.1)

67 (70.5)

28 (29.5)

 

Hyperkalaemia

 Yes

4 (4.0)

3 (75)

1 (25)

1.00

 No

97 (96.0)

68 (70.1)

29 (29.9)

 

Others

 Yes

3 (3.0)

1 (33.33)

2 (66.7)

0.21

 No

98 (97.0)

70 (71.4)

28 (28.6)

 

Death

 Yes

8 (7.9)

2 (25)

6 (75)

0.008*

 No

93 (92.1)

69 (74.2)

24 (25.8)

 
  1. Others: Low blood pressure, multiple premature ventricular complexes
  2. Total n varies slightly for each item due to a small amount of missing data in each
  3. *p value significant at < 0.05 using the Fisher Exact test